Nardine Smoak, MD
Internal Medicine · Clemson, SCNPI 1295362903
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $630 of the $868 with a category attached, or 72.5%. 16 manufacturers reported payments, led by AbbVie at 29.9% of the total. 2025 is the largest year on record at $323, more than ten times the $15 reported in 2021.
Across 34 payments — averaging $25.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$259
- Abbott$239
- Novo Nordisk$68
- Lundbeck LLC$49
- Pfizer$46
- Lilly USA, LLC$28
- plus $179 from 10 others
What the payments were for
- Food & beverage$63073%
- Education$23927%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 13 | $259 |
| Abbott | 1 | $239 |
| Novo Nordisk | 4 | $68 |
| Lundbeck LLC | 2 | $49 |
| Pfizer | 2 | $46 |
| Lilly USA, LLC | 2 | $28 |
| Argenx US, Inc. | 1 | $28 |
| Neurelis, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $18 |
| Tris Pharma Inc | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
| Cardiva Medical, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENSITE$239
How this compares
$868 in reported general payments places this provider in the 65th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 19 | $347 |
| Rosuvastatin Calcium | 33 | $325 |
| Ezetimibe | 16 | $184 |
| Atorvastatin Calcium | 13 | $121 |
| Gabapentin | 11 | $102 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $79 |
| Tamsulosin Hcl | 12 | $71 |
| Lisinopril | 13 | $61 |
| Amlodipine Besylate | 17 | $54 |
| Fluoxetine Hcl | 11 | $30 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Clemson
- Jerry BackNorth Charleston$322K
- Jan BasileCharleston$278K
- Mark PurcellGreenville$165K
- John CleekCharleston$136K
- William BunnHilton Head Island$125K
- Zion LammGreenville$118K
- Bruce GrayGreenville$111K
- Leonard AlsfeldCharleston$91K
- Edward Botse-BaidooMyrtle Beach$90K
- Lisa DarbyGreenville$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.